NASDAQ$CABA
Cabaletta Bio Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Cabaletta Bio reported financial results for the first quarter ended March 31, 2022 and provided a business update.
Cabaletta Bio reported first quarter 2022 financial results, highlighting the progress of its DesCAARTes™ Phase 1 trial and the upcoming first-in-human trial of MuSK-CAART. The company's cash, cash equivalents, and investments totaled $109.2 million as of March 31, 2022, expected to fund operations through Q3 2023.
- DesCAARTes™ trial clinical and translational data from cohorts A3 and A4 and 28-day safety data from cohort A5 expected to be presented at upcoming scientific meetings in mid-2022.
- Multiple abstracts accepted for presentation at upcoming ASGCT and SID Annual Meetings.
- MuSK-CAART first-in-human trial on track to commence in 2022 following Fast Track Designation and IND clearance from the FDA.
- Cabaletta plans to initiate the MusCAARTes™ trial in 2022 and will evaluate MuSK-CAART as a potential treatment for patients with MuSK-associated myasthenia gravis.
Headline financials
Revenue & EPS history
Cabaletta Bio · Revenue · Quarterly
$0
Forward guidance
Cabaletta Bio anticipates several milestones, including presenting clinical data from the DesCAARTes™ trial and initiating the MusCAARTes™ trial. The company expects its current cash reserves to fund operations through the third quarter of 2023.
Tailwinds
- DSG3-CAART: Desmoglein 3 chimeric autoantibody receptor T (DSG3-CAART) cells as a potential treatment for patients with mucosal pemphigus vulgaris (mPV).
- DesCAARTes™ Trial Progressing in Cohort A5
- Multiple upcoming data presentations at American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting and Society For Investigative Dermatology (SID) 2022 Annual Meeting
- MuSK-CAART: Muscle-specific kinase (MuSK) chimeric autoantibody receptor T (MuSK-CAART) cells as a potential treatment for patients with MuSK-associated myasthenia gravis.
- First-in-human trial on track to commence in 2022
Headwinds
- Risk that signs of biologic activity may not inform long-term results
- Risks related to clinical trial site activation or enrollment rates that are lower than expected
- Risks related to unexpected safety or efficacy data observed during clinical studies
- Risks related to the impact of public health epidemics, such as the ongoing COVID-19 pandemic, affecting countries or regions in which we have operations or do business
- Uncertainties related to the initiation and conduct of studies and other development requirements for its product candidates
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2022
+2.7%
Avg return
Earnings day
+3.2%
Avg return
5 days after
+5.3%
Avg return
30 days after
67%
16 / 24 earnings
Positive
+22.7%
Q3 2022
Best reaction
-24.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -7.8% | -9.0% | -16.2% | |
| Q3 2025 | -5.0% | -9.4% | -5.1% | |
| Q1 2025 | -0.6% | +6.9% | -2.9% | |
| Q4 2024 | +12.8% | -28.4% | -14.8% | |
| Q3 2024 | -24.4% | -36.7% | -29.7% | |
| Q1 2024 | +12.4% | +14.7% | -5.1% | |
| Q4 2023 | -4.2% | -6.4% | -26.4% | |
| Q3 2023 | +4.0% | +1.6% | -5.6% | |
| Q2 2023 | +10.0% | +10.4% | +12.0% | |
| Q1 2023 | +1.6% | +7.0% | -1.2% | |
| Q4 2022 | +9.3% | +4.3% | +5.4% | |
| Q3 2022 | +22.7% | +84.0% | +207.2% | |
| Q2 2022 | +19.5% | +17.2% | -26.3% | |
| Q1 2022 | +21.1% | +52.8% | -3.3% | |
| Q4 2021 | +14.6% | +32.7% | +6.4% | |
| Q3 2021 | +2.4% | -5.3% | -19.1% | |
| Q2 2021 | +2.0% | +1.9% | +58.0% | |
| Q1 2021 | -6.6% | -14.0% | -7.2% | |
| Q4 2020 | +1.7% | -4.0% | -8.7% | |
| Q3 2020 | +6.7% | +7.1% | +19.3% | |
| Q2 2020 | +6.4% | +4.6% | -15.8% | |
| Q1 2020 | -9.3% | -8.0% | -8.0% | |
| Q4 2019 | +0.3% | -7.6% | +10.7% | |
| Q3 2019 | -23.7% | -38.7% | +3.7% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro